|Bid||0.00 x 1800|
|Ask||0.00 x 1000|
|Day's range||46.57 - 48.12|
|52-week range||33.32 - 70.00|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||76.38|
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.
The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.